5-(perylen-3-yl)ethynyl-arabino-uridine (aUY11), an arabino-based rigid amphipathic fusion inhibitor, targets virion envelope lipids to inhibit fusion of influenza virus, hepatitis C virus, and other enveloped viruses

Journal of Virology

Volumn 87, Issue 7, 2013, Pages 3640-3654

  Colpitts, Che C ^a,b   Ustinov, Alexey V ^c   Epand, Raquel F ^d   Epand, Richard M ^d   Korshun, Vladimir A ^c   Schanga, Luis M ^a,b,e  

^a Department of Medical Microbiology and Immunology ^*  (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5 (PERYLEN 3 YL)ETHYNYLARABINOURIDINE; ANTIVIRUS AGENT; AUY 11; LIPID; LIPOSOME; NUCLEOSIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; DRUG TARGETING; HEPATITIS C VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; INFLUENZA VIRUS; LIPID BILAYER; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRION; VIRUS ENVELOPE; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS STRAIN;

ANIMALS; ANTIVIRAL AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; CERCOPITHECUS AETHIOPS; DOGS; HEPACIVIRUS; INFLUENZA A VIRUS; LIPOSOMES; MADIN DARBY CANINE KIDNEY CELLS; MEMBRANE LIPIDS; MICE; MICROSCOPY, CONFOCAL; NIH 3T3 CELLS; PEPTIDES; PERYLENE; SPECIES SPECIFICITY; SPECTROMETRY, FLUORESCENCE; URIDINE; VERO CELLS; VIRUS INTERNALIZATION;

HEPATITIS C VIRUS; HUMAN HERPESVIRUS 1; ORTHOMYXOVIRIDAE; VESICULAR STOMATITIS VIRUS;

EID: 84875507361     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02882-12     Document Type: Article

References (58)

1. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C, Webster R, Armour D, Price D, Stammen B, Wood A, Perros M. 2005. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49:4721-4732.
2. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ. 1994. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. U. S. A. 91:9770-9774.
3. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.
4. Harrison SC. 2008. Viral membrane fusion. Nat. Struct. Mol. Biol. 15: 690-698.
5. Earp LJ, Delos SE, Park HE, White JM. 2005. The many mechanisms of viral membrane fusion proteins. Curr. Top. Microbiol. Immunol. 285: 25-66.
6. Chernomordik LV, Kozlov MM. 2003. Protein-lipid interplay in fusion and fission of biological membranes. Annu. Rev. Biochem. 72:175-207.
7. Chernomordik LV, Leikina E, Frolov VA, Bronk P, Zimmerberg J. 1997. An early stage of membrane fusion mediated by the low pH conformation of influenza hemagglutinin depends upon membrane lipids. J. Cell Biol. 136:81-93.
8. Gunther-Ausborn S, Praetor A, Stegmann T. 1995. Inhibition of influenza-induced membrane fusion by lysophosphatidylcholine. J. Biol. Chem. 270:29279-29285.
9. Gaudin Y. 2000. Rabies virus-induced membrane fusion pathway. J. Cell Biol. 150:601-612.
10. Yeagle PL, Smith FT, Young JE, Flanagan TD. 1994. Inhibition of membrane fusion by lysophosphatidylcholine. Biochemistry 33:1820-1827.
11. St Vincent MR, Colpitts CC, Ustinov AV, Muqadas M, Joyce MA, Barsby NL, Epand RF, Epand RM, Khramyshev SA, Valueva OA, Korshun VA, Tyrrell DL, Schang LM. 2010. Rigid amphipathic fusion inhibitors, small molecule antiviral compounds against enveloped viruses. Proc. Natl. Acad. Sci. U. S. A. 107:17339-17344.
12. Andronova VL, Skorobogatyi MV, Manasova EV, Berlin I, Korshun VA, Galegov GA. 2003. Antiviral activity of some 5-arylethynyl 2'-deoxyuridine derivatives. Bioorg. Khim. 29:290-295.
13. Skorobogatyi MV, Ustinov AV, Stepanova IA, Pchelintseva AA, Petrunina AL, Andronova VL, Galegov GA, Malakhov DA, Korshun VA. 2006. 5-Arylethynyl-2=-deoxyuridines, compounds active against HSV-1. Org. Biomol. Chem. 4:1091-1096.
14. Blight KJ, McKeating JA, Rice CM. 2002. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J. Virol. 76: 13001-13014.
15. Lacasse JJ, Schang LM. 2010. During lytic infections, herpes simplex virus type 1 DNA is in complexes with the properties of unstable nucleosomes. J. Virol. 84:1920-1933.
16. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich HG, Mizokami M, Bartenschlager R, Liang TJ. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796.
17. Stoddart CA, Cardin RD, Boname JM, Manning WC, Abenes GB, Mocarski ES. 1994. Peripheral blood mononuclear phagocytes mediate dissemination of murine cytomegalovirus. J. Virol. 68:6243-6253.
18. Lentz BR. 1989. Membrane "fluidity" as detected by diphenylhexatriene probes. Chem. Phys. Lipids 50:171-190.
19. Schmidt AG, Yang PL, Harrison SC. 2010. Peptide inhibitors of denguevirus entry target a late-stage fusion intermediate. PLoS Pathog. 6:e1000851. doi:10.1371/journal.ppat.1000851.
20. Harada S. 2005. The broad anti-viral agent glycyrrhizin directly modulates the fluidity of plasma membrane and HIV-1 envelope. Biochem. J. 392:191-199.
21. Lande MB, Donovan JM, Zeidel ML. 1995. The relationship between membrane fluidity and permeabilities to water, solutes, ammonia, and protons. J. Gen. Physiol. 106:67-84.
22. Harada S, Yusa K, Monde K, Akaike T, Maeda Y. 2005. Influence of membrane fluidity on human immunodeficiency virus type 1 entry. Biochem. Biophys. Res. Commun. 329:480-486.
23. Shinitzky M, Barenholz Y. 1978. Fluidity parameters of lipid regions determined by fluorescence polarization. Biochim. Biophys. Acta 515: 367-394.
24. Epand RM, Epand RF. 1988. Kinetic effects in the differential scanning calorimetry cooling scans of phosphatidylethanolamines. Chem. Phys. Lipids 49:101-104.
25. Epand RM. 1986. Virus replication inhibitory peptide inhibits the conversion of phospholipid bilayers to the hexagonal phase. Biosci. Rep. 6:647-653.
26. Connor J, Yatvin MB, Huang L. 1984. pH-sensitive liposomes: acidinduced liposome fusion. Proc. Natl. Acad. Sci. U. S. A. 81:1715-1718.
27. Wilson IA, Skehel JJ, Wiley DC. 1981. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3A resolution. Nature 289: 366-373.
28. Chen J, Lee KH, Steinhauer DA, Stevens DJ, Skehel JJ, Wiley DC. 1998. Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation. Cell 95:409-417.
29. Wiley DC, Skehel JJ. 1987. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu. Rev. Biochem. 56:365-394.
30. Bullough PA, Hughson FM, Skehel JJ, Wiley DC. 1994. Structure of influenza haemagglutinin at the pH of membrane fusion. Nature 371: 37-43.
31. Krey T, d'Alayer J, Kikuti CM, Saulnier A, Damier-Piolle L, Petitpas I, Johansson DX, Tawar RG, Baron B, Robert B, England P, Persson MA, Martin A, Rey FA. 2010. The disulfide bonds in glycoprotein E2 of hepatitisCvirus reveal the tertiary organization of the molecule. PLoS Pathog. 6:e1000762. doi:10.1371/journal.ppat.1000762.
32. Kielian M. 2006. Class II virus membrane fusion proteins. Virology 344: 38-47.
33. Roche S, Rey RA, Gaudin Y, Bressanelli S. 2007. Structure of the prefusion form of the vesicular stomatitis virus glycoprotein G. Science 315: 843-848.
34. Gaudin Y, Tuffereau C, Segretain D, Knossow M, Flamand A. 1991. Reversible conformational changes and fusion activity of rabies virus glycoprotein. J. Virol. 65:4853-4859.
35. Teissier E, Pecheur EI. 2007. Lipids as modulators of membrane fusion mediated by viral fusion proteins. Eur. Biophys. J. 36:887-899.
36. Chernomordik L. 1996. Non-bilayer lipids and biological fusion intermediates. Chem. Phys. Lipids 81:203-213.
37. Chernomordik LV, Leikina E, Kozlov MM, Frolov VA, Zimmerberg J. 1999. Structural intermediates in influenza haemagglutinin-mediated fusion. Mol. Membr. Biol. 16:33-42.
38. Stiasny K, Heinz FX. 2004. Effect of membrane curvature-modifying lipids on membrane fusion by tick-borne encephalitis virus. J. Virol. 78: 8536-8542.
39. Vogel SS, Leikina EA, Chernomordik LV. 1993. Lysophosphatidylcholine reversibly arrests exocytosis and viral fusion at a stage between triggering and membrane merger. J. Biol. Chem. 268:25764-25768.
40. Bobardt MD, Cheng G, de Witte L, Selvarajah S, Chatterji U, Sanders-Beer BE, Geijtenbeek TB, Chisari FV, Gallay PA. 2008. Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus. Proc. Natl. Acad. Sci. U. S. A. 105:5525-5530.
41. Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV. 2008. A virocidal amphipathic alpha-helical peptide that inhibits hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. U. S. A. 105:3088-3093.
42. Chamoun AM, Chockalingam K, Bobardt M, Simeon R, Chang J, Gallay P, Chen Z. 2012. PD 404,182 is a virocidal small molecule that disrupts hepatitis C virus and human immunodeficiency virus. Antimicrob. Agents Chemother. 56:672-681.
43. Teissier E, Penin F, Pecheur EI. 2011. Targeting cell entry of enveloped viruses as an antiviral strategy. Molecules 16:221-250.
44. Pecheur EI, Lavillette D, Alcaras F, Molle J, Boriskin YS, Roberts M, Cosset FL, Polyak SJ. 2007. Biochemical mechanism of hepatitis C virus inhibition by the broad-spectrum antiviral arbidol. Biochemistry 46: 6050-6059.
45. Villalain J. 2010. Membranotropic effects of arbidol, a broad anti-viral molecule, on phospholipid model membranes. J. Phys. Chem. B 114: 8544-8554.
46. Leneva IA, Russell RJ, Boriskin YS, Hay AJ. 2009. Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol. Antiviral Res. 81:132-140.
47. Teissier E, Zandomeneghi G, Loquet A, Lavillette D, Lavergne JP, Montserret R, Cosset FL, Bockmann A, Meier BH, Penin F, Pecheur EI. 2011. Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol. PLoS One 6:e15874. doi:10.1371/journal.pone .0015874.
48. Boriskin YS, Leneva IA, Pecheur EI, Polyak SJ. 2008. Arbidol: a broadspectrum antiviral compound that blocks viral fusion. Curr. Med. Chem. 15:997-1005.
49. Wolf MC, Freiberg AN, Zhang T, Akyol-Ataman Z, Grock A, Hong PW, Li J, Watson NF, Fang AQ, Aguilar HC, Porotto M, Honko AN, Damoiseaux R, Miller JP, Woodson SE, Chantasirivisal S, Fontanes V, Negrete OA, Krogstad P, Dasgupta A, Moscona A, Hensley LE, Whelan SP, Faull KF, Holbrook MR, Jung ME, Lee B. 2010. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc. Natl. Acad. Sci. U. S. A. 107:3157-3162.
50. Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK. 2007. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc. Natl. Acad. Sci. U. S. A. 104:12772-12777.
51. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D, Matthews T, Johnson MR, Nowak MA, Shaw GM, Saag MS. 1998. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4:1302-1307.
52. Liu R, Tewari M, Kong R, Zhang R, Ingravallo P, Ralston R. 2010. A peptide derived from hepatitis C virus E2 envelope protein inhibits a postbinding step in HCV entry. Antiviral Res. 86:172-179.
53. Huang K, Incognito L, Cheng X, Ulbrandt ND, Wu H. 2010. Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion. J. Virol. 84:8132-8140.
54. Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M. 2010. Synthetic therapeutic peptides: science and market. Drug Discov. Today 15:40-56.
55. Baba M, Miyake H, Wang X, Okamoto M, Takashima K. 2007. Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652. Antimicrob. Agents Chemother. 51:707-715.
56. Iannello A, Debbeche O, Martin E, Attalah LH, Samarani S, Ahmad A. 2006. Viral strategies for evading antiviral cellular immune responses of the host. J. Leukoc. Biol. 79:16-35.
57. Yoshimura A, Kuroda K, Kawasaki K, Yamashina S, Maeda T, Ohnishi S. 1982. Infectious cell entry mechanism of influenza virus. J. Virol. 43: 284-293.
58. Wittels M, Spear PG. 1991. Penetration of cells by herpes simplex virus does not require a low pH-dependent endocytic pathway. Virus Res. 18: 271-290.